This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New RA Data Could Be Magic Pill for Rigel

Rigel Pharmaceuticals (RIGL - Get Report) will release new clinical data next month on an experimental pill for rheumatoid arthritis that could alleviate concerns about the drug's safety and help the company sign a lucrative partnership deal later this year.

The Rigel drug, known as R788, is one of two oral medicines in mid- and late-stage clinical trials as a treatment for rheumatoid arthritis (RA), a progressive disease in which a patient's immune system attacks the bones and cartilage in the body's joints.

The current RA treatment market totals about $14 billion in sales worldwide, with the bulk of that coming from a class of injectable drugs known as "TNF-alpha inhibitors."

Rigel and Pfizer (PFE - Get Report) are locked in a race to develop the first oral pill for RA that could compete with, and perhaps even supplant, the currently dominant TNF-alpha inhibitor drugs -- mainly Johnson & Johnson's (JNJ - Get Report) Remicade; Enbrel, which is sold by Amgen (AMGN - Get Report) and Wyeth (WYE); and Abbott Labs' (ABT - Get Report) Humira.

Rigel, a small drugmaker based in South San Francisco, is conducting two phase II studies of R788 that have enrolled a total of about 650 patients with RA. The company expects to release the first results from these studies in July, followed by another data release in August.

Rigel shares have already begun moving higher as investors anticipate the new R788 data. Rigel shares trading at $8 in late May closed Friday at $11.89. The stock was up 2.7% to $12.21 in recent trading.

A previous and smaller phase II study of R788 released last year showed the drug to be effective at alleviating the pain and joint inflammation suffered by RA patients, but the study was too small to adequately assess R788's safety. RA is a chronic disease requiring patients to take drugs for the rest of their lives, so long-term safety is critical.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ABT $50.50 -0.37%
AMGN $175.59 -0.57%
JNJ $100.02 -0.19%
PFE $36.15 0.25%
RIGL $3.07 3.02%

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs